Research progress of LSD1-based dual-target agents for cancer therapy.
Yang X.
Bioorg Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.bmc.2024.117651 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för domatinostat. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
15 träffarCombination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
Shen L, Wang B, Wang SP, Ji SK, Fu MJ, Wang SW, Hou WQ, Dai XJ, Liu HM.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.3c02133Exploring the potential of histone demethylase inhibition in multi-therapeutic approaches for cancer treatment.
Li D, Liang H, Wei Y, Xiao H, Peng X, Pan W.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115999Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment.
Shirbhate E, Singh V, Jahoriya V, Mishra A, Veerasamy R, Tiwari AK, Rajak H.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115938A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy.
Zhang WX, Huang J, Tian XY, Liu YH, Jia MQ, Wang W, Jin CY, Song J, Zhang SY.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2023.115673Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.
Duan Y, Yu T, Jin L, Zhang S, Shi X, Zhang Y, Zhou N, Xu Y, Lu W, Zhou H, Zhu H, Bai S, Hu K, Guan Y.
Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2023.115367Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications.
Yang FF, Xu XL, Hu T, Liu JQ, Zhou JZ, Ma LY, Liu HM.
J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.2c01527Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
Ojha R, Chen IC, Hsieh CM, Nepali K, Lai RW, Hsu KC, Lin TE, Pan SL, Chen MC, Liou JP.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c00966Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy.
Duan YC, Zhang SJ, Shi XJ, Jin LF, Yu T, Song Y, Guan YY.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.113588Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson JY, Richard S, Raynal NJ.
Clin Epigenetics · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13148-021-01037-1Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Gediya P, Parikh PK, Vyas VK, Ghate MD.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2021.113332Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
Ho TCS, Chan AHY, Ganesan A.
J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.0c00830New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
Rangasamy L, Ortín I, Zapico JM, Coderch C, Ramos A, de Pascual-Teresa B.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.9b00561Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Sarkar R, Banerjee S, Amin SA, Adhikari N, Jha T.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112171HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
Adhikari N, Amin SA, Trivedi P, Jha T, Ghosh B.
Eur J Med Chem · comparative study; review; journal article · DOI 10.1016/j.ejmech.2018.08.081